Lysyl oxidase single-nucleotide polymorphism ( SNP ) ( G 473 A ) is negatively associated with ovarian cancer prognosis

Ovarian cancer is the deadliest of all gynecologic cancers. Lysyl oxidase (LOX) is an extracellular matrix enzyme that catalyzes the cross-linking of collagens or elastin in the extracellular compartment. A novel singlenucleotide polymorphism (SNP) in the LOX gene, G473A (rs1800449), has been reported as being a risk factor for different diseases. To evaluate the association of single-nucleotide polymorphism (SNP) in Lysyl oxidase (LOX) (G473A) with the increased ovarian cancer (OA) risk and the reduced survival of OA patients, TaqMan SNP genotype analysis was performed in 178 OA cases and 121 age-matched controls. Chi-square test and multivariate analysis were used to assess the association of SNP or genotype with clinicopathological characteristics. The survival analysis (overall survival (OS) and recurrence-free survival (RFS)) was performed with the Kaplan-Meier method. Results demonstrated that LOX (G473A) was significantly associated with OA risk (AA vs. GG vs. GA, P = 0.0062). And we observed a greater prevalence of “A” allele (P = 0.0025) in OA patients. It was significantly associated with the tumor differentiation degree (P = 0.0035) or with lymph node metastasis (P = 0.0187). The OS or RFS was significantly different between the two groups (P = 0.0281 for OS, P = 0.0392 for RFS). And the multivariate Cox proportional hazards analysis indicated LOX (AA) genotype was an independent factor for the prognosis of ovarian cancer (P = 0.0452, 1.671 (1.232-5.853)). This study indicates that the LOX variant 473 A>G is correlated with an increase in OA risk. AA genotype had a worse prognosis than GG and GA genotypes. LOXSNP (G473A) may serve as a prognosticator.